Remibrutinib, a novel BTK inhibitor, demonstrates promising efficacy and safety in chronic spontaneous urticaria
Marcus Maurer(Humboldt-Universität zu Berlin), Julian Storim(Novartis (Switzerland)), Adam Reich(Rzeszów University of Technology), Koremasa Hayama(Nihon University), Pauline Walsh(Novartis (Ireland)), Sibylle Haemmerle(Novartis (Switzerland)), William Berger(Northern California Research), Ana M. Giménez‐Arnau(Universitat Autònoma de Barcelona), Summer Xia(AbbVie (United States)), K. Lheritier(Novartis (Switzerland)), Vipul Jain(MIT University)
Cited by 158
Related Papers
The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria
|Allergy|2018|1.4k
The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria
|Allergy|2021|1.2k
Definition of treatment goals for moderate to severe psoriasis: a European consensus
|Archives of Dermatological Research|2010|892